ATE306489T1 - Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel - Google Patents

Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel

Info

Publication number
ATE306489T1
ATE306489T1 AT00909553T AT00909553T ATE306489T1 AT E306489 T1 ATE306489 T1 AT E306489T1 AT 00909553 T AT00909553 T AT 00909553T AT 00909553 T AT00909553 T AT 00909553T AT E306489 T1 ATE306489 T1 AT E306489T1
Authority
AT
Austria
Prior art keywords
sub
deficiency
alkanoyloxy
alkoxy
alkyl
Prior art date
Application number
AT00909553T
Other languages
English (en)
Inventor
Wasimul Haque
James L Charlton
Original Assignee
Medicure Inc
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicure Inc, Univ Manitoba filed Critical Medicure Inc
Application granted granted Critical
Publication of ATE306489T1 publication Critical patent/ATE306489T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT00909553T 1999-03-08 2000-03-07 Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel ATE306489T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12369899P 1999-03-08 1999-03-08
US12588199P 1999-03-24 1999-03-24
PCT/IB2000/000255 WO2000053606A1 (en) 1999-03-08 2000-03-07 Pyridoxal analogues for vitamin b-6 disorders

Publications (1)

Publication Number Publication Date
ATE306489T1 true ATE306489T1 (de) 2005-10-15

Family

ID=26821806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00909553T ATE306489T1 (de) 1999-03-08 2000-03-07 Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel

Country Status (13)

Country Link
US (3) US6339085B1 (de)
EP (1) EP1169322B8 (de)
JP (1) JP2002539127A (de)
AT (1) ATE306489T1 (de)
AU (1) AU763464B2 (de)
BR (1) BR0008857A (de)
CA (1) CA2366602A1 (de)
DE (1) DE60023125T2 (de)
DK (1) DK1169322T3 (de)
ES (1) ES2250112T3 (de)
NZ (1) NZ514567A (de)
PT (1) PT1169322E (de)
WO (1) WO2000053606A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
JP2002539127A (ja) * 1999-03-08 2002-11-19 メディキュア インコーポレーテッド ビタミンｂ−６障害のためのピリドキサル類縁体
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
WO2001013900A2 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
AU784840B2 (en) * 2000-03-28 2006-07-06 Medicure International Inc. Treatment of cerebrovascular disease
AU2006220407B2 (en) * 2000-03-28 2008-06-05 Medicure International Inc. Treatment of cerebrovascular disease
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
WO2004084895A2 (en) * 2003-03-27 2004-10-07 Medicure, Inc. Modulation of cell death
WO2004084910A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
AU2004305154A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
AU2005262228A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
CN101035543A (zh) * 2004-08-10 2007-09-12 麦迪库瑞国际公司 维生素b6相关化合物与ace抑制剂的联合疗法及其治疗糖尿病病症的用途
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
CA2585165A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US20080213364A1 (en) * 2004-11-26 2008-09-04 Medicure International, Inc. Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation
WO2006056078A1 (en) * 2004-11-26 2006-06-01 Medicure International Inc. Novel formulation of pyridoxal 5'-phosphate and method of preparation
WO2006072172A1 (en) * 2005-01-05 2006-07-13 Medicure International Inc. Compounds and methods for regulating triglyceride levels
CA2503087A1 (en) * 2005-03-30 2006-09-30 Medicure International Inc. Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
JP2009517411A (ja) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド 心血管及び関連病状の処置のための調剤
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
US7368828B1 (en) * 2006-03-29 2008-05-06 Calhoon Scott W Wind energy system
WO2007121588A1 (en) * 2006-04-25 2007-11-01 Medicure International Inc. Treatment of atrial fibrillation
US8377911B2 (en) 2009-10-09 2013-02-19 Merck Sharp & Dohme Corp. Diuretics
MX2014000419A (es) 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3206463A (en) 1965-09-14 Pyridoxine aspartate and its process of preparation
FR846376A (fr) 1938-08-23 1939-09-15 Appareillage de navigation aérienne et de bombardement aérien
GB966805A (en) * 1961-05-15 1964-08-19 Merck & Co Inc Process for the preparation of 2-methyl-3-hydroxypyridines
NL120995C (de) 1962-07-05
FR5552M (de) 1966-04-28 1967-11-20
FR5801M (de) 1966-06-27 1968-02-19
GB1228142A (de) 1967-03-31 1971-04-15
FR6453M (de) 1967-06-13 1968-11-12
DE1767499A1 (de) 1968-05-16 1971-09-09 Merck Patent Gmbh Verfahren zur Herstellung haltbarer Vitaminzubereitungen
ES360566A1 (es) 1968-11-22 1970-10-16 Made Labor Sa Un metodo de obtencion de alfa-cetoglutarato de piridoxina y sus derivados.
GB1236531A (en) 1969-02-12 1971-06-23 Soc D Etudes Prod Chimique Adenin derivative
JPS4821959B1 (de) 1969-03-31 1973-07-02
US3910921A (en) 1970-01-08 1975-10-07 Soc D Etudes Prod Chimique Papaverine monopyridoxal phosphate
GB1297080A (de) 1970-04-17 1972-11-22
FR2101010A1 (en) 1970-08-06 1972-03-31 Lyocentre Sparteine mono-and dipyridoxinates and prepn - as tonics for cardiova disorders
GB1493993A (en) 1975-05-16 1977-12-07 Howard A Dietary supplement and dietary methods employing said supplement for the treatment of obesity
US4036844A (en) 1972-04-04 1977-07-19 Beecham Group Limited Aryloxypyridines
US4053607A (en) 1972-04-04 1977-10-11 Beecham Group Limited Aryloxypyridine for treating hyperglycaemia
GB1360536A (en) 1972-04-25 1974-07-17 Soc D Etudes Prod Chimique Pyridoxyl-l-aspartic acid salt
BE790118A (fr) 1972-10-09 1973-02-01 Made Labor Sa Derives de l'alpha-cetoglutarate de pyridoxal et de pyridoxamine,
US4032534A (en) 1973-03-22 1977-06-28 Ferlus-Chimie S.A. Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids
FR2255883A1 (en) 1973-12-28 1975-07-25 Centre Etd Ind Pharma Clofibric acid-vitamin B6 compsns. - with synergistic hypocholesterolaemic and normolipaemic activity
FR2275209A1 (fr) 1974-06-21 1976-01-16 Synthelabo Nouveaux esters cetoniques, leurs sels, leur preparation et les medicaments qui les renferment
FR2276048A1 (fr) 1974-06-27 1976-01-23 Synthelabo Nouveaux esters du cyclohexanol, leurs sels, leur preparation et les medicaments qui les renferment
DE2461742C2 (de) 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB1525885A (en) 1976-05-11 1978-09-20 Soc D Etudes Prod Chimique Vincamine salt of pyridoxal phosphate
JPS5417130A (en) 1977-07-08 1979-02-08 Chugai Pharmaceut Co Ltd Remedy for cardio-vasocular diseases
BE863754A (fr) 1978-02-08 1978-05-29 Dechamps Pierre Nouveaux derives de la vincamine utilisables comme regulateurs de la circulation cerebrale
FR2428640A1 (fr) 1978-06-12 1980-01-11 Parcor Derives de pyridoxine, leur procede de preparation et leur application therapeutique
US4167562A (en) 1978-08-28 1979-09-11 Evers H Ray Method and composition for treating arteriosclerosis
IL62602A (en) 1980-05-19 1984-06-29 Labaz Sanofi Nv Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them
IT1141070B (it) 1980-09-22 1986-10-01 Luso Farmaco Inst Impiego dell'alfa-chetoglutarato di piridossina nella profilassi della iperlattacidemia
CA1184499A (en) 1981-06-29 1985-03-26 David C. Madsen Nutritional composition for management of hepatic failure
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
IN160104B (de) 1983-04-05 1987-06-27 Scras
US4735950A (en) 1983-04-05 1988-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same
US4515771A (en) 1983-04-11 1985-05-07 Fine Daniel H Composition and method for the preventative treatment of dental disease and apparatus for dispensing said composition
GB8330517D0 (en) * 1983-11-16 1983-12-21 Scras 6-vinyl-furo-(3,4-c)pyridine derivatives
GB8330658D0 (en) * 1983-11-17 1983-12-29 Scras 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives
IT1212792B (it) 1983-11-30 1989-11-30 Egidio Aldo Moja Supplemento dietetico e alimento preconfezionato che lo contiene procedimento di preparazione e metodo di somministrazione
US5272165A (en) 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5130324A (en) 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US4567179A (en) 1984-10-11 1986-01-28 Pfizer, Inc. Antiinflammatory salts of piroxicam
DE3519693A1 (de) 1985-06-01 1987-01-02 Basf Ag Pyridin-derivate, ihre herstellung und verwendung
US4837239A (en) 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US4735956A (en) 1985-09-13 1988-04-05 Merck & Co., Inc. Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers
US4605741A (en) 1985-11-13 1986-08-12 Lisapharma Spa Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
NZ222664A (en) 1986-11-29 1990-06-26 Vesta Med Pty Ltd Pharmaceutical compositions containing pyridoxal as a source of vitamin b6
US5254572A (en) 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE3705549A1 (de) 1987-02-18 1988-09-01 Ulrich Speck Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose
US5288716A (en) 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
SE8701662L (sv) 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US5213813A (en) 1987-05-29 1993-05-25 The University Of Vermont Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer
DE58902094D1 (de) 1988-01-28 1992-10-01 Koeltringer Peter Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5254557A (en) * 1988-05-09 1993-10-19 Beecham Group P.L.C. Compound and treatment
FR2641189B1 (fr) 1988-06-20 1991-05-10 Timol Mamoojee Compositions pharmaceutiques contenant de l'acide acetyl salicylique et de la vitamine b6
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5001115A (en) 1989-05-17 1991-03-19 University Of Florida Prodrugs of biologically active hydroxyaromatic compounds
GB8918368D0 (en) 1989-08-11 1989-09-20 Amco Chemie Gmbh Compositions for treating obstructive airways disease
DE4016963A1 (de) 1990-05-25 1991-11-28 Steigerwald Arzneimittelwerk Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben
US5385937A (en) 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
GB2254556B (en) 1991-04-11 1995-04-12 Fisons Plc Formulations containing linolenic acid
RU2126255C1 (ru) 1991-05-15 1999-02-20 Йель Юниверсити Способ получения противоопухолевого эффекта у млекопитающих
FR2678622B1 (fr) 1991-07-03 1994-11-18 Adir Nouveaux complexes de vanadium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0746202A4 (de) 1992-01-06 1997-06-25 Health Maintenance Programs Pharmazeutisch aktive antioxidant enthaltende zusammensetzung und verfahren zu ihrer verwendung in der vorbeugung und behandlung vom restenosis nach angioplastie
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
EP0659083B1 (de) 1992-06-12 1999-12-22 Cephalon, Inc. Vorbeugung und behandlung der peripheren neuropathie
US5330743A (en) 1992-11-12 1994-07-19 Magnetic Research, Inc. Aminosaccharide contrast agents for magnetic resonance images
US5795873A (en) 1992-12-29 1998-08-18 Metabolite Laboratories, Inc. Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6
IT1263957B (it) 1993-02-23 1996-09-05 Impiego terapeutico del pirrolidon carbossilato di piridossina
TW268948B (de) 1993-04-02 1996-01-21 Senju Pharma Co
DE4344751A1 (de) 1993-12-28 1995-06-29 Carl Heinrich Dr Weischer Neue Vitamin B6-Derivate und deren Herstellung und Verwendung als Arzneimittel und als Kosmetika
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
US5569459A (en) 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5733916A (en) 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5833998A (en) 1995-11-06 1998-11-10 The Procter & Gamble Company Topical compositions for regulating the oily/shiny appearance of skin
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5834446A (en) 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
US5770215A (en) 1997-01-06 1998-06-23 Moshyedi; Emil Payman Multivitamin/vascular occlusion inhibiting composition
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5888514A (en) 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
EP0891719A1 (de) 1997-07-14 1999-01-20 N.V. Nutricia Narungszusammensetzungen mit Gehalt an Methionin
US6051587A (en) 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
JP2002539127A (ja) * 1999-03-08 2002-11-19 メディキュア インコーポレーテッド ビタミンｂ−６障害のためのピリドキサル類縁体
WO2001013900A2 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds

Also Published As

Publication number Publication date
US7230009B2 (en) 2007-06-12
DE60023125D1 (de) 2006-02-23
US20030195236A1 (en) 2003-10-16
WO2000053606A1 (en) 2000-09-14
JP2002539127A (ja) 2002-11-19
EP1169322B8 (de) 2006-09-13
PT1169322E (pt) 2007-04-30
DK1169322T3 (da) 2006-03-06
DE60023125T2 (de) 2006-06-22
AU3183400A (en) 2000-09-28
US20010031770A1 (en) 2001-10-18
NZ514567A (en) 2002-11-26
AU763464B2 (en) 2003-07-24
CA2366602A1 (en) 2000-09-14
EP1169322A1 (de) 2002-01-09
EP1169322B1 (de) 2005-10-12
BR0008857A (pt) 2001-12-18
US6339085B1 (en) 2002-01-15
ES2250112T3 (es) 2006-04-16
US6890943B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
DE60023125D1 (de) Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
EA200500814A1 (ru) Производные пирролопиримидина
DE60220403D1 (de) Zusammensetzung zur unterdrückung von magensäure
NO20030895D0 (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
TW200510311A (en) CCr8 inhibitors
SG154333A1 (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
MXPA04003245A (es) Hidroxipropilaminas.
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
NO20025893D0 (no) Veksthormon sekretagoga
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
IL192287A0 (en) Pharmaceutical compositions and methods for use
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
AU6698894A (en) 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
RU2003132465A (ru) Композиция и способы профилактики и лечения рака предстательной железы человека
DE3687181D1 (de) Knochengezielte inhibitoren der karbonischen anhydrase.
DK174389A (da) Anvendelse af 3-substituerede 2-oxindol-1-carboxamid-forbindelser til fremstilling af farmaceutiske praeparater til inhibering af interleukin-1-biosyntese
WO2000071520A3 (en) Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
EP1640005A3 (de) Pyridoxal-Analoge zur Behandlung von Störungen ausgelöst durch einen Vitamin B6 Mangel
DE69911373D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ATE275953T1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
ATE369849T1 (de) Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169322

Country of ref document: EP

REN Ceased due to non-payment of the annual fee